Imported product with medical prescription and authorization from Anvisa is being held by Federal Revenue at Gollog cargo terminal in Guarulhos

Initiative complies with State Law 8,754/22 and aims to prepare professionals to prescribe cannabis safely and legally

Anvisa authorizations for importing cannabidiol in São Paulo increased by 6.2% between January and July 2025, consolidating the state as a leader in requests and reflecting the expanded access through the SUS

New institute aims to connect companies and authorities to overcome regulatory challenges and promote advancements in the medicinal cannabis ecosystem

Understand the step-by-step process to acquire plant derivatives for medicinal purposes

Faced with Anvisa's prohibition on the importation of cannabis flowers, market players diverge in opinions

Resolution No. 365 of the Federal Council of Biomedicine, which authorizes the prescription of traditional herbal products based on cannabidiol by biomedical professionals, clashes with resolutions of the health agency

Resumption of review by Anvisa and final deadline from STJ for cultivation define the sector's direction in the first quarter of the year

The event brings together experts, companies, and authorities to discuss regulatory advances, research, and innovation in cannabis-based therapies, connecting the entire public and private sector

Political representatives of health and public safety in South Africa point to an increase in illegal offers and misuse of licenses in accessing medicinal cannabis

The expansion of the industry and the transformation in patients' lives

Debates on medicinal cannabis continue deeply at Cannabis Connection 2025 in November and at the Brazilian Medicinal Cannabis Congress in May 2026, both in São Paulo.

COFFITO Ruling No. 735/2024 authorizes physical therapists with specific training to prescribe medications and supplies; however, Anvisa recognizes only doctors and dentists as prescribers of cannabis for medicinal purposes

Learn How to Access Cannabis Products Through the Unified Health System and Understand the Obligations of Health Insurance Providers

Resolution No. 1,015/2026 tightens technical requirements, expands sanitary controls, and consolidates authorization as a transitional step before the registration of medicines

Rômison Rodrigues Mota leaves the position after a request for review delays the norm's vote; the topic will return to the regulatory agenda for 2026-2027

Submission of registrations, videos, and requests for confidentiality ends at 11:59 pm this Friday (5); item revising rules for cannabis products will be defined at the Dicol meeting on December 10

Anvisa's update "mirrors" the rules for controlling cannabis products directly in the list of controlled substances and defines classification for industrial inputs

According to Filipe Campos, from Close-Up International, the market could expand even further with rule updates and greater medical adherence

On Deusa Cast, lawyer Larissa Meneghel details how the five-year deadline set forth in RDC-327 for clinical cannabis research works and comments on the renewal proposal under review by Anvisa